Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 93 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

ECRI and the Institute for Safe Medication Practices PSO - P0008
Component of Parent Org(s):
  • Emergency Care Research Institute d/b/a ECRI
    • Parent Organization Alternate Legal Name: ECRI
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 5200 Butler Pike, Plymouth Meeting, PA 19462
PSO Phone Number: 866-247-3004
Point of Contact: Sheila Rossi MHA
Point of Contact Phone: 610-825-6000, ext. 5281
Point of Contact Email: srossi@ecri.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
HCA Patient Safety Organization, LLC - P0157
Component of Parent Org(s):
  • HCA Holdings, Inc. (direct parent: EP Holdco, LLC)
Effective Date and Time of Initial Listing: April 9, 2014 12:01 AM ET
PSO Mailing Address: P.O. Box 750, Nashville, TN 37202
PSO Phone Number: 615-344-2293
Point of Contact: Rhonda Kaye Kollenborn
Point of Contact Phone: 615-344-5372
Point of Contact Email: Rhonda.Kollenborn@hcahealthcare.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/09/2020 through 04/08/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Nebraska Coalition for Patient Safety - P0076
Component of Parent Org(s):
  • Nebraska Academy of Physician Assistants
  • Nebraska Hospital Association
  • Nebraska Medical Association
  • Nebraska Nurses Association
  • Nebraska Pharmacists Association
  • Nebraska Pharmacists' Association
Effective Date and Time of Initial Listing: October 14, 2009 12:01 AM ET
PSO Mailing Address: 986055 Nebraska Medical Center, Omaha, NE 68198-6055
PSO Phone Number: 402-559-8421
Point of Contact: Gail E Brondum LPN
Point of Contact Phone: 402-559-8421
Point of Contact Email: gail.brondum@unmc.edu (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 10/14/2019 through 10/13/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
UHS Acute Care PSO - P0110
Component of Parent Org(s):
  • UHS of Delaware, Inc.
Effective Date and Time of Initial Listing: April 22, 2014 12:01 AM ET
PSO Mailing Address: 367 South Gulph Road, King of Prussia, PA 19406
PSO Phone Number: 610-382-3385
Point of Contact: Heidi Speirs
Point of Contact Phone: 610-382-1057
Point of Contact Email: heidi.speirs@uhsinc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 04/22/2020 through 04/21/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes
Vizient™ PSO - P0007
Component of Parent Org(s):
  • Vizient Inc
Effective Date and Time of Initial Listing: November 5, 2008 12:01 AM ET
PSO Mailing Address: 155 North Wacker Drive, 40th floor, Chicago, IL 60606
PSO Phone Number: 312-775-4100
Point of Contact: Ellen M. Flynn RN, MBA, JD
Point of Contact Phone: 312-775-4100
Point of Contact Email: Ellen.Flynn@vizientinc.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/05/2020 through 11/04/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No